Discovery of novel irreversible inhibitors of IL-2 inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket

John D Harling, Angela M Deakin, Sébastien Campos, Rachel Grimley, Laiq Chaudry, Catherine Nye, Oxana Polyakova, Christina M Bessant, Nick Barton, Don Somers, John Barrett, Rebecca H Graves, Laura Hanns, W. J. Kerr, Roberto Solari

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

IL-2 inducible tyrosine kinase (Itk) plays a key role in antigen receptor signalling in T cells and is considered an important target for anti-inflammatory drug discovery. In order to generate inhibitors with the necessary potency and selectivity, a compound that targeted Cysteine442 in the ATP binding pocket and with an envisaged irreversible mode of action was designed. We incorporated a high degree of molecular recognition and specific design features making the compound suitable for inhaled delivery. This study confirms the irreversible covalent binding of the inhibitor to the kinase by X-ray crystallography and enzymology, whilst demonstrating potency, selectivity, and prolonged duration of action in in vitro biological assays. The biosynthetic turnover of the kinase was also examined as a critical factor when designing irreversible inhibitors for extended duration of action. The exemplified Itk inhibitor demonstrated inhibition of both TH1 and TH2 cytokines, was additive with fluticasone propionate and inhibited cytokine release from human lung fragments. Finally, we describe an in vivo pharmacodynamic assay that allows rapid preclinical development without animal efficacy models.
LanguageEnglish
Pages28195-28206
Number of pages12
JournalJournal of Biological Chemistry
Issue number39
Early online date9 Aug 2013
DOIs
Publication statusPublished - 2013

Fingerprint

TYK2 Kinase
Protein-Tyrosine Kinases
Cysteine
Assays
Phosphotransferases
Adenosine Triphosphate
Pharmacodynamics
Cytokines
Molecular recognition
Antigen Receptors
T-cells
X ray crystallography
X Ray Crystallography
Drug Discovery
Biological Assay
Interleukin-2
Animals
Anti-Inflammatory Agents
Animal Models
T-Lymphocytes

Keywords

  • IL-2 inducible tyrosine kinase
  • Itk
  • tyrosine kinase
  • kinase inhibitor
  • novel irreversible inhibitors

Cite this

Harling, John D ; Deakin, Angela M ; Campos, Sébastien ; Grimley, Rachel ; Chaudry, Laiq ; Nye, Catherine ; Polyakova, Oxana ; Bessant, Christina M ; Barton, Nick ; Somers, Don ; Barrett, John ; Graves, Rebecca H ; Hanns, Laura ; Kerr, W. J. ; Solari, Roberto. / Discovery of novel irreversible inhibitors of IL-2 inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket. In: Journal of Biological Chemistry. 2013 ; No. 39. pp. 28195-28206.
@article{afa2b7ce302e433f8822df94d3307713,
title = "Discovery of novel irreversible inhibitors of IL-2 inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket",
abstract = "IL-2 inducible tyrosine kinase (Itk) plays a key role in antigen receptor signalling in T cells and is considered an important target for anti-inflammatory drug discovery. In order to generate inhibitors with the necessary potency and selectivity, a compound that targeted Cysteine442 in the ATP binding pocket and with an envisaged irreversible mode of action was designed. We incorporated a high degree of molecular recognition and specific design features making the compound suitable for inhaled delivery. This study confirms the irreversible covalent binding of the inhibitor to the kinase by X-ray crystallography and enzymology, whilst demonstrating potency, selectivity, and prolonged duration of action in in vitro biological assays. The biosynthetic turnover of the kinase was also examined as a critical factor when designing irreversible inhibitors for extended duration of action. The exemplified Itk inhibitor demonstrated inhibition of both TH1 and TH2 cytokines, was additive with fluticasone propionate and inhibited cytokine release from human lung fragments. Finally, we describe an in vivo pharmacodynamic assay that allows rapid preclinical development without animal efficacy models.",
keywords = "IL-2 inducible tyrosine kinase, Itk, tyrosine kinase, kinase inhibitor, novel irreversible inhibitors",
author = "Harling, {John D} and Deakin, {Angela M} and S{\'e}bastien Campos and Rachel Grimley and Laiq Chaudry and Catherine Nye and Oxana Polyakova and Bessant, {Christina M} and Nick Barton and Don Somers and John Barrett and Graves, {Rebecca H} and Laura Hanns and Kerr, {W. J.} and Roberto Solari",
year = "2013",
doi = "10.1074/jbc.M113.474114",
language = "English",
pages = "28195--28206",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
number = "39",

}

Harling, JD, Deakin, AM, Campos, S, Grimley, R, Chaudry, L, Nye, C, Polyakova, O, Bessant, CM, Barton, N, Somers, D, Barrett, J, Graves, RH, Hanns, L, Kerr, WJ & Solari, R 2013, 'Discovery of novel irreversible inhibitors of IL-2 inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket' Journal of Biological Chemistry, no. 39, pp. 28195-28206. https://doi.org/10.1074/jbc.M113.474114

Discovery of novel irreversible inhibitors of IL-2 inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket. / Harling, John D; Deakin, Angela M; Campos, Sébastien ; Grimley, Rachel; Chaudry, Laiq; Nye, Catherine; Polyakova, Oxana; Bessant, Christina M; Barton, Nick; Somers, Don; Barrett, John; Graves, Rebecca H; Hanns, Laura; Kerr, W. J.; Solari, Roberto.

In: Journal of Biological Chemistry, No. 39, 2013, p. 28195-28206.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Discovery of novel irreversible inhibitors of IL-2 inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket

AU - Harling, John D

AU - Deakin, Angela M

AU - Campos, Sébastien

AU - Grimley, Rachel

AU - Chaudry, Laiq

AU - Nye, Catherine

AU - Polyakova, Oxana

AU - Bessant, Christina M

AU - Barton, Nick

AU - Somers, Don

AU - Barrett, John

AU - Graves, Rebecca H

AU - Hanns, Laura

AU - Kerr, W. J.

AU - Solari, Roberto

PY - 2013

Y1 - 2013

N2 - IL-2 inducible tyrosine kinase (Itk) plays a key role in antigen receptor signalling in T cells and is considered an important target for anti-inflammatory drug discovery. In order to generate inhibitors with the necessary potency and selectivity, a compound that targeted Cysteine442 in the ATP binding pocket and with an envisaged irreversible mode of action was designed. We incorporated a high degree of molecular recognition and specific design features making the compound suitable for inhaled delivery. This study confirms the irreversible covalent binding of the inhibitor to the kinase by X-ray crystallography and enzymology, whilst demonstrating potency, selectivity, and prolonged duration of action in in vitro biological assays. The biosynthetic turnover of the kinase was also examined as a critical factor when designing irreversible inhibitors for extended duration of action. The exemplified Itk inhibitor demonstrated inhibition of both TH1 and TH2 cytokines, was additive with fluticasone propionate and inhibited cytokine release from human lung fragments. Finally, we describe an in vivo pharmacodynamic assay that allows rapid preclinical development without animal efficacy models.

AB - IL-2 inducible tyrosine kinase (Itk) plays a key role in antigen receptor signalling in T cells and is considered an important target for anti-inflammatory drug discovery. In order to generate inhibitors with the necessary potency and selectivity, a compound that targeted Cysteine442 in the ATP binding pocket and with an envisaged irreversible mode of action was designed. We incorporated a high degree of molecular recognition and specific design features making the compound suitable for inhaled delivery. This study confirms the irreversible covalent binding of the inhibitor to the kinase by X-ray crystallography and enzymology, whilst demonstrating potency, selectivity, and prolonged duration of action in in vitro biological assays. The biosynthetic turnover of the kinase was also examined as a critical factor when designing irreversible inhibitors for extended duration of action. The exemplified Itk inhibitor demonstrated inhibition of both TH1 and TH2 cytokines, was additive with fluticasone propionate and inhibited cytokine release from human lung fragments. Finally, we describe an in vivo pharmacodynamic assay that allows rapid preclinical development without animal efficacy models.

KW - IL-2 inducible tyrosine kinase

KW - Itk

KW - tyrosine kinase

KW - kinase inhibitor

KW - novel irreversible inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84884794348&partnerID=8YFLogxK

U2 - 10.1074/jbc.M113.474114

DO - 10.1074/jbc.M113.474114

M3 - Article

SP - 28195

EP - 28206

JO - Journal of Biological Chemistry

T2 - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 39

ER -